Why Raloxifene? This is why:

**jimmyinkedup** · 10-09-2015, 08:23 AM

J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

Comment in:

* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.
* J Pediatr. 2005 Apr;146(4):576; author reply 576-7.

Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia .
Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
Department of Pediatrics, University of Ottawa, Ontario, Canada.

[email protected]

OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifene in the medical management of persistent pubertal gynecomastia.

STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).

RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

PMID: 15238910 [PubMed - indexed for MEDLINE]

**NACH3** · 10-09-2015, 08:27 AM

Thx for sharing Jimmy.... Great as always!

Maybe we can add some ongoing cases w/ralox and tamox from members experiences on here - I'm currently running ralox so I'd be happy to share my experiences in the farther future!

**kelkel** · 10-09-2015, 08:39 AM

Originally Posted by jimmyinkedup

J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

Those are the numbers that surprise me as I've seen studies showing only a percentage or two difference.

Good find.

**Splifton** · 10-09-2015, 09:09 AM

Interesting study. I wouldn't have anticipated these results with consideration to tamoxifine's longer terminal half life in comparison to raloxifene.

**jimmyinkedup** · 10-09-2015, 09:30 AM

In a way the study surprises me as I wouldnt expect that much of a difference. Then again knowing ralox has a stronger binding affinity to the e receptor in breast tissue maybe I shouldnt be that surprised. I was glad to find this as it so directly applies to us andx our use of the compounds. It rare to find something so directly applicable to us study wise.

**Splifton** · 10-09-2015, 03:25 PM

Do you think it's just the superiority for ER binding affinity in general or something related to it's selectivity of ER sites associated with breast tissue/mammary glands? I'm honestly wondering why I've never read any academic literature regarding the comparison, but I can't remember the last time I found SERM studies having any relevance to males.

**jimmyinkedup** · 10-09-2015, 04:21 PM

Originally Posted by Splifton

Do you think it's just the superiority for ER binding affinity in general or something related to it's selectivity of ER sites associated with breast tissue/mammary glands? I'm honestly wondering why I've never read any academic literature regarding the comparison, but I can't remember the last time I found SERM studies having any relevance to males.

I definitely feel it is the specific high binding affinity to the e receptor in breast tissue specifically that is responsible for any difference. It would indicate that while all serms are selective the selectivity varies depending upon which serm is being used. Of course this is just my opinion but it think the data bears it out so I feel OK drawing such a conclusion.

**max738** · 10-09-2015, 07:56 PM

I have only seen a few studies reguarding serms and males I believe there will be more in the furture ralox has been shown to lower LDL by as much as almost 20% in one study that I have seen but doesn't affect HDL.I'm on a big dose of a statin and ralox dropped my LDL quite a bit I've been taking it for about 2 months.I do agree with jimmy different serms act a little differently but I know there are studies going on with ralox and lowering CAD risk